Literature DB >> 23339767

Psychiatric symptoms in adults with phenylketonuria.

Deborah A Bilder1, Barbara K Burton, Hilary Coon, Lauren Leviton, James Ashworth, Bridget D Lundy, Hazel Vespa, Amanda V Bakian, Nicola Longo.   

Abstract

BACKGROUND: The objective of this study was to identify psychiatric symptom patterns reported by individuals with phenylketonuria (PKU) in the outpatient clinic setting.
METHODS: Brief Symptom Inventory (BSI) results, phenylalanine (phe) levels, and demographic information were collected through a retrospective chart review on 64 participants in the study, "A Diversified Approach for PKU Treatment" (ADAPT).
RESULTS: The number of BSI scores meeting clinical threshold was significantly elevated for all global indexes and 6 out of 7 symptom subscales in patients with PKU. Recent and mean phe levels were correlated with age at the time of screening (R(2)=0.10, R(2)=0.10, respectively; p<0.05). Psychoticism and the Positive Symptom Distress Index (PSDI) scores were associated with metabolic control.
CONCLUSIONS: The results of this study demonstrate a positive correlation between phe levels and psychiatric symptom severity in individuals with PKU.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23339767     DOI: 10.1016/j.ymgme.2012.12.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  22 in total

1.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

2.  Creatine plus pyruvate supplementation prevents oxidative stress and phosphotransfer network disturbances in the brain of rats subjected to chemically-induced phenylketonuria.

Authors:  Vanessa Trindade Bortoluzzi; Letícia Brust; Thales Preissler; Itiane Diehl de Franceschi; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

3.  A Multiplatform Metabolomics Approach to Characterize Plasma Levels of Phenylalanine and Tyrosine in Phenylketonuria.

Authors:  H Blasco; C Veyrat-Durebex; M Bertrand; F Patin; F Labarthe; H Henique; P Emond; C R Andres; C Antar; C Landon; L Nadal-Desbarats; F Maillot
Journal:  JIMD Rep       Date:  2016-06-15

4.  Hyperphenylalaninemia Correlated with Global Decrease of Antioxidant Genes Expression in White Blood Cells of Adult Patients with Phenylketonuria.

Authors:  Charlotte Veyrat-Durebex; Christelle Debeissat; Hélène Blasco; Franck Patin; Hélène Henique; Patrick Emond; Catherine Antar; Valérie Gissot; Olivier Herault; François Maillot
Journal:  JIMD Rep       Date:  2017-03-15

5.  Improved Measurement of Brain Phenylalanine and Tyrosine Related to Neuropsychological Functioning in Phenylketonuria.

Authors:  Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin
Journal:  JIMD Rep       Date:  2016-09-28

6.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

7.  Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.

Authors:  Vincent M Isabella; Binh N Ha; Mary Joan Castillo; David J Lubkowicz; Sarah E Rowe; Yves A Millet; Cami L Anderson; Ning Li; Adam B Fisher; Kip A West; Philippa J Reeder; Munira M Momin; Christopher G Bergeron; Sarah E Guilmain; Paul F Miller; Caroline B Kurtz; Dean Falb
Journal:  Nat Biotechnol       Date:  2018-08-13       Impact factor: 54.908

8.  Creatine nanoliposome reverts the HPA-induced damage in complex II-III activity of the rats' cerebral cortex.

Authors:  Nathana Jamille Mezzomo; Diego Becker Borin; Francine Ianiski; Barbara Dotto Fontana; Itiane Diehl de Franceschi; Juliane Bolzan; Renata Garcez; Mateus Grings; Belisa Parmeggiani; Liana da Silva Fernandes; Rodrigo de Almeida Vaucher; Guilhian Leipnitz; Clovis Milton Duval Wannmacher; Virginia Cielo Rech
Journal:  Mol Biol Rep       Date:  2019-08-13       Impact factor: 2.316

9.  Modeling the cognitive effects of diet discontinuation in adults with phenylketonuria (PKU) using pegvaliase therapy in PAH-deficient mice.

Authors:  Shelley R Winn; Sandra Dudley; Tanja Scherer; Nicole Rimann; Beat Thöny; Sydney Boutros; Destine Krenik; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2022-03-21       Impact factor: 4.204

10.  Elevated levels of plasma phenylalanine in schizophrenia: a guanosine triphosphate cyclohydrolase-1 metabolic pathway abnormality?

Authors:  Olaoluwa Okusaga; Olesja Muravitskaja; Dietmar Fuchs; Ayesha Ashraf; Sarah Hinman; Ina Giegling; Annette M Hartmann; Bettina Konte; Marion Friedl; Jason Schiffman; Elliot Hong; Gloria Reeves; Maureen Groer; Robert Dantzer; Dan Rujescu; Teodor T Postolache
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.